Conditions: B-Cell Chronic Lymphocytic Leukemia
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 184
Healthy volunteers: no

Brief summary:
The purpose of this research study is to find out what effects (good and bad) the combination of Nipent+Cytoxan+Rituxan has on CLL cancer compared to Fludara+Cytoxan+Rituxan. While all of these drugs are approved by the Food and Drug Administration (FDA) for the treatment of other cancers, these combinations are experimental for the treatment of CLL.

Detailed description:

Arms:
arm 1: Fludarabine, Cyclophosphamide, and Rituximab (dosage based on day in cycle) arm 2: Pentostatin, Cyclophosphamide, and Rituximab (dosage depends on day in cycle)

Interventions: intervention 1: Fludarabine intervention 2: Cyclophosphamide intervention 3: Rituximab intervention 4: Pentostatin
Intervention descriptions: intervention 1: None intervention 2: None intervention 3: None intervention 4: None

Protocol document: